Fluid coating from a polymer solution

International audienceNew experiments on coating of a wire with aqueous poly(ethylene oxide) solutions are reported. If these experiments are compared with coating with a pure Liquid of the same physical characteristics, a strong thickening of the liquid layer is observed. This effect is described by considering the normal stresses, which allows us to obtain an analytical expression for the coated thickness in good agreement with the data

Le mouillage dynamique des fibres

International audienceWe discuss how a solid (especially a fiber) is coated when drawn out of a bath of liquid. 1. For slow withdrawals out of pure viscous liquids, the data are found to be fitted by the famous Landau law: then, the coating results from a balance between viscosity and capillarity. For quicker withdrawals, the thickness of the entrained film suddenly diverges, at a velocity on order 1 m/s. Inertia is shown to be responsible for this effect. At still higher velocities, the thickness decreases with the velocity because the solid can only entrain the viscous boundary layer. 2. For complex fluids, surface effects are found in the low velocity regime: out of a surfactant solution, films are thicker than predicted by Landau, by a factor of order 2. The thickening factor is shown to be fixed by the Marangoni flow due to the presence of surfactants; out of an emulsion, the film can be enriched with oil, which can be understood by a simple model of capture; out of a polymer solution, a strong swelling of the film is observed if normal stresses are present. Hence, the problem has two families of solution: (i) at low velocity, the thickness of the layer is fixed by a balance between viscous and surface forces and thus is sensitive to the presence of surfactants, or other heterogeneities; (ii) at high velocity, inertia must be considered and the film thickness is fixed by the bulk properties of the liquid (density and viscosity). In these regimes, it is not affected by the presence of surfactants in the bath

The correlations with identity companion automorphism, of finite Desarguesian planes

AbstractAs a first step towards the general classification of correlations of finite Desarguesian planes, we present, up to isomorphism, all the correlations with identity companion automorphism which are not polarities, of such planes

Floating with seeds: understanding hydrochorous mangrove propagule dispersal: a field and modeling approach

Présentation avec posterinfo:eu-repo/semantics/publishedYoung Marine Scientists’ Day Vlaams Instituut voor de Zee (VLIZ), 24 février, Brugge, Belgiqu

Caught in transit: offshore interception of seafaring propagules from seven mangrove species

Many organisms are transported passively and make use of the energy of natural phenomena or other organisms to disperse. However, not all species are equally likely to disperse over long distances. In mangroves, which possess seafaring propagules, it is largely unknown which species are more likely to reach the ocean and contribute to long‐distance dispersal. This is because dispersal has been mainly studied under reductionist laboratory conditions and via localized release–recapture experiments. Direct interceptions of propagules at sea have hardly been attempted because of the high labor intensity. Here, we set up a local citizen‐science network and engaged local fishermen to collect floating mangrove propagules over a period of 27 months. By comparing the dispersing community of propagules from the local stands in which they were produced, the open water of the bay, and the open ocean beyond the coral reef barrier, we could study the transition between local and long‐distance dispersal. The composition of the dispersing community changed from the local stands toward the ocean, suggesting that this transition imposes an important selective filter for leaving the local system. With the exception of three rare species (Lumnitzera racemosa, Pemphis acidula, and Xylocarpus moluccensis), we intercepted dispersing propagules of every mangrove species occurring in the East African region. Most intercepted propagules were produced by Rhizophora mucronata and Ceriops tagal, followed by Bruguiera gymnorrhiza and Avicennia marina, which also represent the most abundant species in the nearby mangrove forest. A larger number of propagules were intercepted during the wet season, with fewer propagules recovered during the dry season. Overall, our study indicates that differences in the dispersal capacity of mangrove propagules are not straightforward and that some species may better disperse at local scales within an estuary or embayment, while others might be more suitable for dispersal over longer distances. The presence of such trade‐offs may help explain why current attempts to use mangrove traits to predict mangrove species distributions at different scales have remained only moderately successful

Shapes, contact angles, and line tensions of droplets on cylinders

Using an interface displacement model we calculate the shapes of nanometer-size liquid droplets on homogeneous cylindrical surfaces. We determine effective contact angles and line tensions, the latter defined as excess free energies per unit length associated with the two contact lines at the ends of the droplet. The dependences of these quantities on the cylinder radius and on the volume of the droplets are analyzed.Comment: 26 pages, RevTeX, 10 Figure

Surface shape reconstruction from phaseless scattered acoustic data using a random forest algorithm

Recent studies have demonstrated that acoustic waves can be used to reconstruct the roughness profile of a rigid scattering surface. In particular, the use of multiple microphones placed above a rough surface as well as an analytical model based on the linearised Kirchhoff integral equations provides a sufficient base for the inversion algorithm to estimate surface geometrical properties. Prone to fail in the presence of high noise and measurement uncertainties, the analytical approach may not always be suitable in analysing measured scattered acoustic pressure. With the aim to improve the robustness of the surface reconstruction algorithms, here it is proposed to use a data-driven approach through the application of a random forest regression algorithm to reconstruct specific parameters of one-dimensional sinusoidal surfaces from airborne acoustic phase-removed pressure data. The data for the training set are synthetically generated through the application of the Kirchhoff integral in predicting scattered sound, and they are further verified with data produced from laboratory measurements. The surface parameters from the measurement sample were found to be recovered accurately for various receiver combinations and with a wide range of noise levels ranging from 0.1% to 30% of the average scattered acoustical pressure amplitude

Non-typeable Haemophilus influenzae protein vaccine in adults with COPD:A phase 2 clinical trial

Loss of airway microbial diversity is associated with non-typeable Haemophilus influenzae (NTHi) infection and increased risk of exacerbation in chronic obstructive pulmonary disease (COPD). We assessed the safety and immunogenicity of an investigational vaccine containing NTHi antigens, recombinant protein D (PD) and combined protein E and Pilin A (PE-PilA), and AS01 adjuvant in adults with moderate/-severe COPD and prior exacerbations. In this phase 2, observer-blind, controlled trial (NCT02075541), 145 COPD patients aged 40-80 years randomly (1:1) received two doses of NTHi vaccine or placebo 60 days apart, on top of standard care. Reactogenicity in the 7-day post-vaccination period was higher following NTHi vaccine than placebo. Most solicited adverse events (AEs) were mild/moderate. At least one unsolicited AE was reported during the 30-day post-vaccination period by 54.8% of NTHi vaccine and 51.4% of placebo recipients. One serious AE (placebo group) was assessed by the investigator as vaccine-related. Anti-PD, anti-PE and anti-PiIA geometric mean antibody concentrations increased up to 30 days after each NTHi vaccine dose, waned thereafter, but remained higher than baseline (non-overlapping confidence intervals) up to 13 months post-dose 2. The frequency of specific CD4(+) T cells increased following two doses of NTHi vaccine and remained higher than baseline. Exploratory analysis showed a statistically non-significant lower yearly rate of moderate/severe exacerbations in the NTHi vaccine group than following placebo (1.49 versus 1.73) in the one-year period post-dose 2, with estimated vaccine efficacy of 13.3% (95% confidence interval -24.2 to 39.5; p = 0.44). The NTHi vaccine had an acceptable safety and reactogenicity profile and good immunogenicity in adults with COPD

Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study.

BACKGROUND: The ongoing Ebola outbreak led to accelerated efforts to test vaccine candidates. On the basis of a request by WHO, we aimed to assess the safety and immunogenicity of the monovalent, recombinant, chimpanzee adenovirus type-3 vector-based Ebola Zaire vaccine (ChAd3-EBO-Z). METHODS: We did this randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a trial at the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. Participants (aged 18-65 years) were randomly assigned (2:2:1), via two computer-generated randomisation lists for individuals potentially deployed in endemic areas and those not deployed, to receive a single intramuscular dose of high-dose vaccine (5 × 10(10) viral particles), low-dose vaccine (2·5 × 10(10) viral particles), or placebo. Deployed participants were allocated to only the vaccine groups. Group allocation was concealed from non-deployed participants, investigators, and outcome assessors. The safety evaluation was not masked for potentially deployed participants, who were therefore not included in the safety analysis for comparison between the vaccine doses and placebo, but were pooled with the non-deployed group to compare immunogenicity. The main objectives were safety and immunogenicity of ChAd3-EBO-Z. We did analysis by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT02289027. FINDINGS: Between Oct 24, 2014, and June 22, 2015, we randomly assigned 120 participants, of whom 18 (15%) were potentially deployed and 102 (85%) were non-deployed, to receive high-dose vaccine (n=49), low-dose vaccine (n=51), or placebo (n=20). Participants were followed up for 6 months. No vaccine-related serious adverse events were reported. We recorded local adverse events in 30 (75%) of 40 participants in the high-dose group, 33 (79%) of 42 participants in the low-dose group, and five (25%) of 20 participants in the placebo group. Fatigue or malaise was the most common systemic adverse event, reported in 25 (62%) participants in the high-dose group, 25 (60%) participants in the low-dose group, and five (25%) participants in the placebo group, followed by headache, reported in 23 (57%), 25 (60%), and three (15%) participants, respectively. Fever occurred 24 h after injection in 12 (30%) participants in the high-dose group and 11 (26%) participants in the low-dose group versus one (5%) participant in the placebo group. Geometric mean concentrations of IgG antibodies against Ebola glycoprotein peaked on day 28 at 51 μg/mL (95% CI 41·1-63·3) in the high-dose group, 44·9 μg/mL (25·8-56·3) in the low-dose group, and 5·2 μg/mL (3·5-7·6) in the placebo group, with respective response rates of 96% (95% CI 85·7-99·5), 96% (86·5-99·5), and 5% (0·1-24·9). Geometric mean concentrations decreased by day 180 to 25·5 μg/mL (95% CI 20·6-31·5) in the high-dose group, 22·1 μg/mL (19·3-28·6) in the low-dose group, and 3·2 μg/mL (2·4-4·9) in the placebo group. 28 (57%) participants given high-dose vaccine and 31 (61%) participants given low-dose vaccine developed glycoprotein-specific CD4 cell responses, and 33 (67%) and 35 (69%), respectively, developed CD8 responses. INTERPRETATION: ChAd3-EBO-Z was safe and well tolerated, although mild to moderate systemic adverse events were common. A single dose was immunogenic in almost all vaccine recipients. Antibody responses were still significantly present at 6 months. There was no significant difference between doses for safety and immunogenicity outcomes. This acceptable safety profile provides a reliable basis to proceed with phase 2 and phase 3 efficacy trials in Africa. FUNDING: Swiss State Secretariat for Education, Research and Innovation (SERI), through the EU Horizon 2020 Research and Innovation Programme